 Jun Inamo
Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 9 | 2023 | 1004 | 3.000 |
Why?
| | Scleroderma, Systemic | 2 | 2021 | 97 | 1.380 |
Why?
| | Mendelian Randomization Analysis | 4 | 2020 | 45 | 1.250 |
Why?
| | Gastrointestinal Microbiome | 2 | 2020 | 503 | 0.880 |
Why?
| | Scleroderma, Diffuse | 1 | 2020 | 4 | 0.730 |
Why?
| | Sjogren's Syndrome | 1 | 2020 | 42 | 0.710 |
Why?
| | B-Lymphocyte Subsets | 1 | 2020 | 67 | 0.690 |
Why?
| | Churg-Strauss Syndrome | 1 | 2019 | 17 | 0.670 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2020 | 129 | 0.670 |
Why?
| | Foot Bones | 1 | 2018 | 11 | 0.650 |
Why?
| | Skin Diseases | 1 | 2020 | 124 | 0.640 |
Why?
| | Synovitis | 1 | 2018 | 24 | 0.640 |
Why?
| | Antirheumatic Agents | 1 | 2021 | 255 | 0.630 |
Why?
| | Rheumatoid Factor | 1 | 2019 | 157 | 0.620 |
Why?
| | Enthesopathy | 1 | 2018 | 2 | 0.620 |
Why?
| | Tenosynovitis | 1 | 2018 | 12 | 0.620 |
Why?
| | Ultrasonography, Doppler | 1 | 2018 | 105 | 0.620 |
Why?
| | Arthralgia | 1 | 2018 | 50 | 0.620 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2020 | 222 | 0.610 |
Why?
| | Genome-Wide Association Study | 3 | 2023 | 1301 | 0.610 |
Why?
| | Celiac Disease | 1 | 2020 | 266 | 0.580 |
Why?
| | Ankle Joint | 1 | 2018 | 155 | 0.560 |
Why?
| | Models, Theoretical | 1 | 2020 | 527 | 0.540 |
Why?
| | Transcriptome | 1 | 2021 | 742 | 0.530 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 343 | 0.490 |
Why?
| | Coronavirus Infections | 1 | 2020 | 335 | 0.490 |
Why?
| | Autoantibodies | 1 | 2021 | 1362 | 0.440 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2020 | 0.420 |
Why?
| | Transcription Factors | 1 | 2020 | 1531 | 0.410 |
Why?
| | Gene Expression Profiling | 3 | 2021 | 1548 | 0.340 |
Why?
| | Machine Learning | 3 | 2023 | 319 | 0.330 |
Why?
| | Humans | 17 | 2023 | 115907 | 0.290 |
Why?
| | Antineoplastic Agents | 1 | 2018 | 1891 | 0.290 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2020 | 2091 | 0.290 |
Why?
| | Skin | 2 | 2021 | 668 | 0.270 |
Why?
| | Apolipoprotein E4 | 1 | 2023 | 33 | 0.230 |
Why?
| | Apolipoproteins E | 1 | 2023 | 81 | 0.230 |
Why?
| | Abatacept | 1 | 2021 | 40 | 0.190 |
Why?
| | DNA Topoisomerases, Type I | 1 | 2021 | 17 | 0.190 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2021 | 27 | 0.190 |
Why?
| | RNA Polymerase III | 1 | 2021 | 25 | 0.190 |
Why?
| | Remission Induction | 1 | 2021 | 240 | 0.190 |
Why?
| | SOXC Transcription Factors | 1 | 2020 | 5 | 0.180 |
Why?
| | Myositis | 1 | 2021 | 43 | 0.180 |
Why?
| | Germinal Center | 1 | 2020 | 46 | 0.180 |
Why?
| | Causality | 1 | 2020 | 106 | 0.180 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2021 | 90 | 0.180 |
Why?
| | Immunoglobulin A | 1 | 2021 | 173 | 0.170 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2021 | 193 | 0.170 |
Why?
| | Middle Aged | 4 | 2021 | 27084 | 0.160 |
Why?
| | Principal Component Analysis | 1 | 2019 | 181 | 0.160 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 233 | 0.160 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2021 | 340 | 0.160 |
Why?
| | Asymptomatic Diseases | 1 | 2018 | 77 | 0.150 |
Why?
| | Pulmonary Alveoli | 1 | 2021 | 376 | 0.150 |
Why?
| | Retrospective Studies | 3 | 2019 | 12616 | 0.150 |
Why?
| | Biopsy | 1 | 2021 | 1056 | 0.140 |
Why?
| | Risk Factors | 2 | 2020 | 8714 | 0.140 |
Why?
| | Male | 5 | 2021 | 56128 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 253 | 0.140 |
Why?
| | Immunoglobulin G | 1 | 2021 | 782 | 0.140 |
Why?
| | Female | 5 | 2021 | 60086 | 0.140 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2021 | 686 | 0.140 |
Why?
| | Pain Measurement | 1 | 2018 | 450 | 0.140 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1359 | 0.140 |
Why?
| | Computer Simulation | 1 | 2020 | 887 | 0.130 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2021 | 965 | 0.130 |
Why?
| | Lung Diseases, Interstitial | 1 | 2021 | 520 | 0.130 |
Why?
| | B-Lymphocytes | 1 | 2020 | 771 | 0.130 |
Why?
| | Incidence | 1 | 2020 | 2333 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 1817 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1758 | 0.110 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2598 | 0.110 |
Why?
| | Ovarian Neoplasms | 1 | 2018 | 407 | 0.110 |
Why?
| | Pandemics | 1 | 2020 | 1333 | 0.100 |
Why?
| | Risk Assessment | 1 | 2020 | 3004 | 0.100 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 4449 | 0.090 |
Why?
| | Aged | 2 | 2019 | 19299 | 0.090 |
Why?
| | Prognosis | 1 | 2018 | 3342 | 0.090 |
Why?
| | Aged, 80 and over | 1 | 2019 | 6438 | 0.080 |
Why?
| | Quality of Life | 1 | 2018 | 2392 | 0.070 |
Why?
| | Treatment Outcome | 1 | 2021 | 9166 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2018 | 2207 | 0.060 |
Why?
| | Apolipoprotein E3 | 1 | 2023 | 4 | 0.060 |
Why?
| | DNA, Complementary | 1 | 2023 | 262 | 0.060 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2023 | 53 | 0.060 |
Why?
| | Cell Death | 1 | 2023 | 324 | 0.050 |
Why?
| | Interleukin-10 | 1 | 2023 | 304 | 0.050 |
Why?
| | Macrophages, Alveolar | 1 | 2023 | 357 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2021 | 273 | 0.040 |
Why?
| | Computational Biology | 1 | 2023 | 528 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2021 | 609 | 0.040 |
Why?
| | Fibroblasts | 1 | 2023 | 838 | 0.040 |
Why?
| | Adult | 1 | 2019 | 30820 | 0.040 |
Why?
| | Macrophages | 1 | 2023 | 1281 | 0.030 |
Why?
|
|
Inamo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|